Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 6/20 | 0.60 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7904909 | 0.84 | RAB9A (0.67) | ITGB3ITGA2BRAB9APOLB | |
| SCHEMBL13336896 | 0.80 | ITGB3 (0.56) | ITGB3ITGA2B | |
| SCHEMBL4716271 | 0.80 | ITGB3 (0.56) | ITGB3ITGA2BRAB9A | |
| SCHEMBL21765666 | 0.80 | RAB9A (0.71) | RAB9APOLB | |
| SCHEMBL12501320 | 0.80 | ITGB3 (0.58) | ITGB3ITGA2B | |
| SCHEMBL28366098 | 0.79 | NPC1 (0.64) | RAB9APOLB | |
| SCHEMBL29975245 | 0.79 | NPC1 (0.64) | RAB9APOLB | |
| SCHEMBL531907 | 0.78 | CYP1A2 (0.55) | ITGB3ITGA2BRAB9A | |
| SCHEMBL29606520 | 0.78 | ITGB3 (0.54) | ITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL4761772 | 0.77 | ITGB3 (0.55) | ITGB3ITGA2BRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358736-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | Intermune, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010045266-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | ITGB3 2731/4885ITGA2B 3047/4885RAB9A 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.